Prior to vaccine availability, RSV was a significant cause of illness and hospitalization in older adults in the U.S., ...

GSK and Pfizer’s full-year financial results show that the former is currently winning the battle for take-up of their rival respiratory syncytial virus (RSV) vaccines, although, there are signs ...

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

The Government of Canada has secured an initial supply of 500,000 doses of GSK's bird flu vaccine to protect individuals most ...

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...

GSK has secured approval from the US Food and Drug Administration (FDA) for its new vaccine, Penmenvy, to protect against five meningococcal serogroups for individuals aged ten to 25. The vaccine ...

Claims on social media suggest Pfizer's COVID vaccine has fatal side effects, referencing a US House document. However, the report includes adverse events, not side effects. Adverse events ...

GSK’s five-in-one ... protection against the five vaccine-preventable serogroups in one vaccine and making it easier for adolescents to get the coverage they need.” The authorisation follows the FDA’s ...